最新临床试验：波马度胺联合地塞米松是否联用伊沙佐米来治疗复发性多发性骨髓瘤

这是经美国国家癌症研究所批准的一项多中心随机对照 I / II期临床试验，目的是研究与地塞米松合用时，波马度胺和伊沙佐米的副作用和最佳剂量，并观察波马度胺和地塞米松联合或不联合伊沙佐米对治疗复发的多发性骨髓瘤患者的疗效。生物疗法，如波马度胺和地塞米松，可能以不同的方式刺激免疫系统，阻止癌细胞生长。伊沙佐米可能通过阻断细胞生长所需的某些酶来阻止癌细胞的生长。目前尚不清楚波马度胺和地塞米松联合或不联合伊沙佐米治疗多发性骨髓瘤是否更有效。

该临床试验在全美306家医院进行开展。

This randomized phase I / II trial studies the side effects and best dose of pomalidomide and ixazomib when given together with dexamethasone and to see how well pomalidomide and dexamethasone with or without ixazomib works in treating patients with multiple myeloma that has come back. Biological therapies, such as pomalidomide and dexamethasone, may stimulate the immune system in different ways and stop cancer cells from growing. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether pomalidomide and dexamethasone are more effective with or without ixazomib in treating multiple myeloma.

Trial IDs